- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulation of ciprofibrate
Mixed hyperlipidaemia when statin is contraindicated or not tolerated
Severe hypertriglyceridaemia with or without low HDL cholesterol
100 mg daily.
Do not exceed this dose.
100 mg daily.
Do not exceed this dose.
Patients with Renal Impairment
Moderate renal impairment
100 mg on alternate days with careful monitoring.
The Renal Drug Handbook suggests the following doses:
Glomerular renal function (GFR)
GFR 20 to 50 ml/minute: Dose as in normal renal function.
GFR 10 to 20 ml/minute: 100 mg every 48 hours.
GFR less than 10 ml/minute: Avoid.
Children under 18 years
Creatine kinase levels over 5 times upper limit of normal
Photoallergic or phototoxic reactions to fibrates
Gall bladder disorder
Severe hepatic impairment
Severe renal impairment
Precautions and Warnings
High alcohol intake
Patients over 70 years
Glucose-galactose malabsorption syndrome
History of muscular toxicity secondary to fibrates
History of muscular toxicity secondary to HMG-CoA reductase inhibitors
History of non-traumatic rhabdomyolysis
Reduce dose in patients with moderate renal impairment
Advise ability to drive/operate machinery may be affected by side effects
Correct hypothyroidism before treatment
Exclude/correct secondary causes of dyslipidaemia prior to treatment
Monitor hepatic function periodically
Monitor serum transaminases every 3 months during first 12 months of use
Review if an adequate response not obtained within 3 months
Advise patients to report muscle pain/tenderness/weakness
Discontinue if abnormal liver function tests persist or worsen
Discontinue if myopathy is suspected
Discontinue if ALT level exceeds 3 times the upper limit of normal
Discontinue if AST level exceeds 3 times the upper limit of normal
Discontinue if CPK rises progressively
Discontinue if CPK rises to > or equal to 5x upper limit of normal range
Discontinue if creatine kinase concentration increases significantly
Discontinue immediately if rhabdomyolysis occurs
Dietary restrictions should be maintained
Patients should not exceed recommended dose
Pregnancy and Lactation
Ciprofibrate is contraindicated in pregnancy.
At the time of writing there is limited published experience concerning the use of ciprofibrate during human pregnancy. No evidence of teratogenicity has been found but high doses of ciprofibrate have shown signs of embryotoxicity in animal studies. Schaefer concludes that fibrates should not be prescribed during pregnancy, however inadvertent treatment with lipid reducers during pregnancy does not necessitate either termination of the pregnancy or invasive diagnostic procedures (Schaefer, 2007).
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Ciprofibrate is contraindicated in breastfeeding.
At the time of writing there is limited published experience concerning the use of ciprofibrate during breastfeeding. Ciprofibrate is excreted in the milk of lactating rats, however no data is available from human studies.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Abnormal liver function tests
Creatine phosphokinase increased
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last full review: July 2015
Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.
Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.
Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press Accessed on 15 July 2015.
Martindale: The Complete Drug Reference (online) London: Brayfield A (ed). Pharmaceutical Press Accessed on 13 July 2015.
Summary of Product Characteristics: Ciprofibrate 100mg tablets. Zentiva. Revised January 2014.
The Renal Drug Handbook. Fourth Edition (2014) ed. Ashley, C and Dunleavy, A, Radcliffe Publishing Ltd, London.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.